All the Active Ingredient Drugs
PPI. Pantoprazole 20 mg. E.C. TABS: 30. Adult. & adolesc. 12 yrs. of
age and above: Reflux dis. and assoc.
symp. (e.g. heartburn, acid
regurgitation, pain on swallowi.)-
20mg×1/d. Symp. relief is gener.
accompl. within 2-4 wks. If this is not
suffic., symp. relief will normal. be
achieved within a further 4 wks. When
symp. relief has been achieved,
reoccurring symp. can be control. using
an on-demand regimen of 20mg×1/d,
taking one tab. when requir.
Long-term manag.& preven. of relapse
in reflux esophag.: Mainten. dose- is 20
mg×1/d is recomm., incr. to 40 mg ×1/d
if a relapse occurs.After heal. of the
relapse the dose can be reduced again
to 20 mg.
Adults: Preven. of gastroduod. ulc.
induced by NSAIDs in pts. at risk with a
need for contin. NSAID tmt.:
Tmt. of reflux esophagitis & assoc. symp.
(e.g. heartburn, acid regurgitation, pain
on swallow.). For long-term manag. &
prevent. of relapse in reflux esophagitis.
Preven. of gastroduodenal ulc. induced
by NSAIDs in pts. at risk with a need for
continuous NSAIDs tmt.
C/I: Hypersens., subst. benzimidazoles. Comb. ther. for the eradication of H. pylori in pts. with renal impair. or severe hep. impair.
PPI. Pantoprazole 40 mg. E.C. TABS: 14, 28. Tmt. mod-severe
GERD: Adults/adolesc. 12 yrs and
above: 1 tab x dly. Erad. H. pylori in
comb. with 2 approp. antibiotics:
Adults: Depend. On resist. pattern: a) 2
x dly: 1 x 40 mg +1,000 mg amoxillin +
500 mg clarithromycin; b) 2 x dly: 1 x
40 mg + 500 mg metronidazole + 500
mg clarithromycin; c) 2 x dly: 1 x 40 mg
+ 1,000 mg amoxicillin + 500 mg
metronidazole. If comb. ther. not an
option: Monother. as follows: Tmt.
gastric/duod. ulc: 1 tab dly.
Zollinger-Ellison syndr. + other
hypersecret. conds: Long-term
manage: Initial: 80 mg dly. Can titrate
up/ down as reqd. Doses above 80 mg
dly to be div. into 2 doses.
Pts. with hep. impair.: dly. dose of 20
mg exceed. in pts. with sev. hep.
impair, must not be used in comb. tmt.
For eradic. H. pylori in pts. with moder.
– sev. hep. dysfunc. since curren. no
data are availab. on the effic. & safety
of Pantoprazole in comb. tmt. of these
Short term tmt. of acute duod. ulcer,
acute gastric ulcer, mod./sev. reflux
esophagi., eradic. of H. pylori in comb.
With clarithromycin and amoxycillin
orclarithromycin and metronidazole or
amoxicillin and metronidazole in cases of
duoden. ulcer & gastric ulcer with the
object. of reduc. of duod./gastr.ulc.
caused by this microorganism, Zollinger
C/I: Hypersens., subst. benzimidazoles .
Comb. ther. for the eradication of H.
pylori in pts. with renal impair. or severe
PPI. Pantoprazole (as sodium) 40 mg/vial. VIAL: 1. Duodenal ulcer, gastric ulc., moderate and severe reflux oesophagitis: 40 mg (1 vial) ×1/d.
Zollinger-Ellison-Syndr.: For the long-term manag. of Zollinger-Ellison-Syndr. pts. should start their tmt. with a dly. dose of 80 mg. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secret. to guide. With doses above 80 mg dly., the dose should be divided and given twice dly. A temporary incr. of the dose above 160 mg is possible but should not be applied longer than requir. for adequate. acid control.
In case a rapid acid control is requir, a start. dose of 80 mg×2/d. is suffic. to manage a decrease of acid output into the target range (<10 mEq/h) within 1h in the majority of pts.
Duodenal ulcer. Gastric ulcer. Moderate and severe reflux oesophagitis. Zollinger-Ellison-Syndrome.
C/I: Hypersens. to the active subst., substitut. benzimidazoles and any of the excipients.
PPI. Pantoprazole (as sodium) 40 mg/vial. VIAL (pwdr. for inject.): 1, 20. I.V. admin. only if oral admin. not appropriate. Duoden. ulcer, gastric ulcer, mod., severe reflux
esophagit: 40 mg dly. Long term manage
Zollinger-Ellison Syndr./other path.
hypersecret. conds: Initial: 80 mg dly.
Titrate up/down as req. Above 80 mg, div.
into 2 dly doses. See lit. Replace I.V.
formula by oral formula when clin.
Duoden./gastric ulc., mod., severe reflux
esophagit., Zollinger-Ellison Syndr., other
path. hypersecret. conds.
C/I: Hypersens., co-admin. with atzanavir